Pages

.

Showing posts with label Advisory. Show all posts
Showing posts with label Advisory. Show all posts

Media Advisory: NXT-ID Demo's Wocket™ Smart Wallet Financial Transaction

SHELTON, Conn., June 13, 2014 /PRNewswire/ -- NXT-ID, Inc. (OTCQB: NXTD), a biometric authentication company focused on the growing m-commerce market, releases a video of the next generation smart wallet, Wocket™, designed to replace all the cards in your wallet, executing a financial transaction.

Mr. Gino Pereira, CEO of NXT-ID, Inc. explains step-by-step how to make a Wocket transaction:

"All your important personal information is secured on a tamper-proof encrypted chip on your Wocket, so if you were to lose your wallet, there is no payment information available to be stolen. Using your Wocket is simple:

1. To access a card for payment, you would first verify your identity by using a spoken password (Wocket recognizes your voice), or by entering a PIN or image on the touch screen.

2. Touch the drop-down menu at the top left of the screen. You will see a list of categories such as debit, credit, loyalty etc. and select the appropriate category.

3. Choose the card you wish to use on the touchscreen and remove the WocketCard from your Wocket.

4. Swipe your WocketCard as you would any regular credit card.

Wocket is also capable of producing a "wocket number" which is a one-time use encrypted card number to prevent skimming attacks and protect your private card information. This technology can also be applied to online transactions, making card processing much more secure using today's existing payment infrastructure."

See demo video at https://www.youtube.com/watch?v=EMUpEMv9O2Y

Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.

Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.

Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.

The Wocket retails for $149.99. Advance order a Wocket at: http://www.wocketwallet.com/

About NXT-ID Inc. - Mobile Security for a Mobile World

NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.wocketwallet.com/

NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Forward-Looking Statements for NXT-ID

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Contact

Corporate info: info@nxt-id.com
Investor inquiries:
Kirin Smith, ProActive Capital Group
Direct: +1-646-863-6519
ksmith@proactivecrg.com
Media: 800-665-0411

SOURCE NXT-ID, Inc.

reade more... Résuméabuiyad

Biosyntrx, Inc. Announces New Scientific Advisory Board Members

Steps to the Harvard Library Center of Knowledge. (PRNewsFoto/Biosyntrx, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";COLORADO SPRINGS, Colo., Feb. 18, 2014 /PRNewswire/ -- Biosyntrx, Inc., a nutritional biotechnology and healthy lifestyles education company in the ophthalmic sector is proud to announce the addition of three new scientific advisory board members:

(Photo: http://photos.prnewswire.com/prnh/20140218/SF65884)

Lucy Young, MD, is Associate Professor of Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. She is the director of the Lancaster Course in Ophthalmology and has been on its faculty since 1990. Her publication list includes 95 peer review papers and book chapters. She is on the Best Doctors and U.S. News & World Report Top Doctors lists.

Richard Davis, MD, is a physician, inventor, and successful serial entrepreneur who has authored nearly 400 patents and trademarks worldwide, as well as sold four start-up companies to publicly traded companies. He is currently serving as the Chairman, President, and CEO of OgenX Therapeutics, a privately held mitochondrial medicines company focusing on solutions in Neurodegeneration, Oncology, and Virology in humans and animals.

Vincent de Luise, MD, is Assistant Clinical Professor of Ophthalmology at Yale University School of Medicine and Adjunct Clinical Assistant Professor of Ophthalmology at Weill Cornell Medical College. He serves on the editorial boards of the Cornea Journal and Eye World. As a post-doctoral fellow at Harvard University this past year, he developed a rubric for medical humanities education at both the undergraduate and medical school level.

About Biosyntrx, Inc.: Biosyntrx is a Colorado Springs, Colo.–based Nutritional Biotechnology Company with emphasis on ophthalmic nutrition science, professional crosstalk, and healthy lifestyles education. The primary Biosyntrx Eye Care Professional–recommended products are BioTears, a patented product that addresses the systemic nutrient needs of the dry eye patient, with millions of doses safely used by satisfied repeat customers, Macula Complete, a potent full-spectrum multiple designed for the those concerned about AMD, cataract, diabetic retinopathy, glaucoma, lack of energy, and optimal full-body health, also with millions of doses safely used by satisfied repeat customers. Oculair, a less potent full-body multiple, SightC+ for those who want or need daily or occasional megadoses of mineral-buffered vitamin C, Zeaxanthin-4 for those who want a 4 mg standalone zeaxanthin product, and EpiCor, a clinically proven immune system modulator. ?

For additional information, contact Biosyntrx CEO, Ellen Troyer, at etroyer@biosyntrx.com or office 719-227-7888 or cell 719-660-6676

SOURCE Biosyntrx, Inc.

RELATED LINKS
http://www.biosyntrx.com

reade more... Résuméabuiyad